<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442024000500004</article-id>
<article-id pub-id-type="doi">10.24875/rmn.24000023</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Multidisciplinary consensus on the combined management of Alzheimer’s disease by Mexican experts: recommendations and guidelines]]></article-title>
<article-title xml:lang="es"><![CDATA[Consenso multidisciplinario sobre el manejo combinado de la enfermedad de Alzheimer por expertos mexicanos: recomendaciones y lineamientos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peña-de León]]></surname>
<given-names><![CDATA[Edilberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alberch-Junghanns]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Genchi]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Ruiz]]></surname>
<given-names><![CDATA[Minerva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macías-Osuna]]></surname>
<given-names><![CDATA[Amador E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Carrillo]]></surname>
<given-names><![CDATA[Francisco M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Bermudez]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Díaz]]></surname>
<given-names><![CDATA[Santiago P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-García]]></surname>
<given-names><![CDATA[Ramiro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Barba]]></surname>
<given-names><![CDATA[Bernardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres-Cid de León]]></surname>
<given-names><![CDATA[Agustín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Investigaciones en Sistema Nervioso Central Centro de Investigaciones en Sistema Nervioso Central (CISNE) ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Puebla Sociedad Española de Beneficiencia de Puebla Former Head of Teaching]]></institution>
<addr-line><![CDATA[Puebla City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Psiquatría "Juan Ramón de la Fuente" Sleep Clinic ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Academia Mexicana de Neurología A.C. Former President ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Clinical Research Coordinator of Geriatrics Specialty ITESM Alzheimer Association General Director ]]></institution>
<addr-line><![CDATA[Monterrey City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Academia Mexicana de Neurología A.C. Instituto Nacional de Neurología y Neurocirugía Secretary of the Dementia/Geriatric Study Group ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Universidad Cuahutemoc, Aguascalientes campus Head of the Neuropsychiatry Unit ]]></institution>
<addr-line><![CDATA[Aguascalientes City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Universidad Cuahutemoc campus Aguascalientes Professor of Geriatrics and Research ]]></institution>
<addr-line><![CDATA[Aguascalientes City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Instituto Nacional de Neurología y Neurocirugía Deputy Director of Teaching ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Hospital Ángeles del Pedregal. Founder of the Geriatrics Service of the Hospital General Regional 72 IMSS Geriatrics Department ]]></institution>
<addr-line><![CDATA[Estado de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A11">
<institution><![CDATA[,Hospital Español Psychogeriatrics Department ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>25</volume>
<numero>5</numero>
<fpage>138</fpage>
<lpage>142</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442024000500004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442024000500004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442024000500004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: Alzheimer’s disease (AD), affecting over 55 million people globally, poses a substantial public health challenge. Early diagnosis and appropriate treatment are vital to slowing its progression and enhancing patient quality of life. The fixed-dose combination of citicoline with rivastigmine emerges as a promising strategy AD treatment.  Methods: A real-time Delphi consensus was reached with the participation of 11 Mexican experts.  Results: The combination offers neuroprotective benefits, enhancing neuronal regeneration and reducing glutamate levels linked to neuronal damage in AD. These effects translate into improved cognitive function and delayed cognitive decline in AD.  Conclusions: The Mexican Consensus for the Combined Management of AD endorses this fixed-dose combination of rivastigmine with citicoline as a new therapeutic perspective. Its efficacy and safety make it a valuable option for the treatment of this neurodegenerative disease.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: La enfermedad de Alzheimer, que afecta a más de 55 millones de personas en todo el mundo, representa un desafío creciente para la salud pública. El diagnóstico temprano y el tratamiento adecuado son fundamentales para ralentizar su progresión y mejorar la calidad de vida de los pacientes. En este contexto, la combinación de dosis fija de citicolina con rivastigmina emerge como una estrategia prometedora en el tratamiento de la EA.  Métodos: Se llevó a cabo un consenso mediante la metodología Delphi en tiempo real con la participación de 11 expertos mexicanos.  Resultados: La combinación de dosis fija de citicolina con rivastigmina ofrece beneficios de neuroprotección al tiempo que aumenta la regeneración neuronal y reduce los niveles de glutamato, asociado con el daño neuronal en la EA. Estos efectos se traducen en mejoras en la función cognitiva a partir de los 3 meses de iniciado el tratamiento, así como en el retraso del deterioro cognitivo en la EA.  Conclusiones: El Consenso Mexicano para el Manejo Combinado de la Enfermedad de Alzheimer respalda esta combinación de dosis fija de rivastigmina con citicolina como una nueva perspectiva terapéutica para la enfermedad de Alzheimer. Su eficacia y seguridad la convierten en una opción valiosa para el tratamiento de esta enfermedad neurodegenerativa.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Alzheimer’s disease]]></kwd>
<kwd lng="en"><![CDATA[Citicoline]]></kwd>
<kwd lng="en"><![CDATA[Rivastigmine]]></kwd>
<kwd lng="en"><![CDATA[Cholinesterase inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Fixed dose combination]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad de Alzheimer]]></kwd>
<kwd lng="es"><![CDATA[Citicolina]]></kwd>
<kwd lng="es"><![CDATA[Rivastigmina]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de la colinesterasa]]></kwd>
<kwd lng="es"><![CDATA[Combinación a dosis fija]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Dementia]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thami]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Nhan]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mauskopf]]></surname>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of clinical practice guideline for Alzheimer's disease and strategies for future advancements]]></article-title>
<source><![CDATA[Neurol Ther]]></source>
<year>2023</year>
<volume>12</volume>
<page-range>1257-84</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alzheimer's disease drug development pipeline:2023]]></article-title>
<source><![CDATA[Alzheimers Dement]]></source>
<year>2023</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauzon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repurposed agents in the Alzheimer's disease drug development pipeline]]></article-title>
<source><![CDATA[Alzheimers Res Ther]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>98</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castagna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cotroneo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Ruotolo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gareri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The CITIRIVAD study:CITIcoline plus RIVAstigmine in elderly patients affected with dementia study]]></article-title>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2016</year>
<volume>36</volume>
<page-range>1059-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gareri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Castagna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cotroneo]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Putrignao]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Conforti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Santamaria]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The citicholinage study:citicoline plus cholinesterase inhibitors in aged patients affected with Alzheimer's disease study]]></article-title>
<source><![CDATA[J Alzheimers Dis]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>557-65</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gnatzy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Warth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[von der Gracht]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Darkow]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validating an innovative real-time Delphi approach - A methodological comparison between real-time and conventional Delphi studies]]></article-title>
<source><![CDATA[Technol Forecast Soc Change]]></source>
<year>2011</year>
<volume>78</volume>
<page-range>1681-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<source><![CDATA[California Evidence Code - Section 720:article 1. Expert Witnesses Generally]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<source><![CDATA[PRISMA]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taber]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Use of Cronbach's Alpha when developing and reporting research instruments in science education]]></article-title>
<source><![CDATA[Res Sci Educ]]></source>
<year>2018</year>
<volume>48</volume>
<page-range>1273-96</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prasath]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sumathi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of Alzheimer's disease by imaging:a comprehensive review]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2023</year>
<volume>20</volume>
<page-range>1273</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Weng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer's disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations]]></article-title>
<source><![CDATA[Front Aging Neurosci]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>1013295</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libre-Rodriguez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alzheimer's disease:update on its prevention, diagnosis and treatment]]></article-title>
<source><![CDATA[Rev Haban Cienc Med]]></source>
<year>2022</year>
<volume>21</volume>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thangaraju]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Babu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Venkatesan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fixed-dose combinations:an essential for rational preparation]]></article-title>
<source><![CDATA[Indian J Pharmacol]]></source>
<year>2021</year>
<volume>53</volume>
<page-range>170-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
